FindTrial
Sign In

Oral Fluid Sars-CoV-2 Ab Rapid test

Rapid point-of-care oral fluid screening test for Sars-CoV-2 antibodies to monitor COVID-19 disease - O-CovAb

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/06/026044
Enrollment
100
Registered
2020-06-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Asian Healthcare Foundation
Lead Sponsor
DiabetOmics
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. 18 years or older, men and women 2. Subjects suspected or with symptoms of Sars-CoV-2 3. Subjects, 3 days after the onset of symptoms 4. Smoking or non-smoking 5. Subjects willing for participating in the study and providing informed consent

Exclusion criteria

Exclusion criteria: Subjects on ventilators or lung support

Design outcomes

Primary

MeasureTime frame
There is a significant positive correlation between presence or absence of (blood and salivary) antibodies (against Sars-CoV-19 virus) and, severity and duration of disease after onset of symptoms.Timepoint: 4 July - 19 August 2020—

Secondary

MeasureTime frame
It is also hypothesized that there is a significant positive correlation between presence or absence of (blood and salivary) antibodies (against Sars-CoV-19 virus) and, severity and duration of disease.Timepoint: 4 July - 19 August 2020—

Countries

India

Contacts

Public ContactVishnupriya Rao Paturi

Asian Institute of Gastroenterology

aigres.mit@gmail.com9247164730

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026